Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Current Assets (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Current Assets for 14 consecutive years, with $28.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Assets rose 7.64% year-over-year to $28.0 million, compared with a TTM value of $28.0 million through Sep 2025, up 7.64%, and an annual FY2024 reading of $26.0 million, up 4.32% over the prior year.
  • Current Assets was $28.0 million for Q3 2025 at Sunshine Biopharma, roughly flat from $27.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $42.0 million in Q2 2022 and bottomed at $1.8 million in Q2 2021.
  • Average Current Assets over 5 years is $22.1 million, with a median of $25.7 million recorded in 2024.
  • The sharpest move saw Current Assets surged 5313.51% in 2021, then crashed 37.84% in 2023.
  • Year by year, Current Assets stood at $2.2 million in 2021, then surged by 1143.83% to $27.3 million in 2022, then dropped by 8.87% to $24.9 million in 2023, then grew by 4.32% to $26.0 million in 2024, then increased by 7.71% to $28.0 million in 2025.
  • Business Quant data shows Current Assets for SBFM at $28.0 million in Q3 2025, $27.9 million in Q2 2025, and $24.5 million in Q1 2025.